<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02069106</url>
  </required_header>
  <id_info>
    <org_study_id>1001-PR-003-09092013</org_study_id>
    <nct_id>NCT02069106</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Daily Pro-Omega LDL for Low-Density Lipoprotein Cholesterol and Triglyceride Reduction</brief_title>
  <acronym>PrOteCT</acronym>
  <official_title>An 8-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Daily Pro-Omega LDL for Low-Density Lipoprotein Cholesterol and Triglyceride Reduction in Subjects With Mixed Hyperlipoproteinemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nordic Pharma, USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nutrasource Pharmaceutical and Nutraceutical Services, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nordic Pharma, USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pro-Omega LDL reduces low-density lipoprotein cholesterol and triglycerides in subjects with&#xD;
      mixed hyperlipoproteinemia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Low-density lipoprotein cholesterol (LDL-C)</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Triglycerides (TG)</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total cholesterol</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High-density lipoprotein cholesterol (HDL-C)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non-HDL-C</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL-C/HDL-C ratio</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Offset effect</measure>
    <time_frame>2 weeks after withdrawal</time_frame>
    <description>Offset effect of Pro-Omega LDL two weeks after withdrawal of placebo and Pro-Omega LDL on serum markers</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Mixed Hyperlipoproteinemia</condition>
  <arm_group>
    <arm_group_label>Pro-Omega LDL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 capsules 1000 mg BID for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 capsules BID for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Pro-Omega LDL</intervention_name>
    <arm_group_label>Pro-Omega LDL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women, ≥18 years of age.&#xD;
&#xD;
          -  History (&gt;3months) of LDL-C ≥130 mg/dl to ≤190 mg/dL&#xD;
&#xD;
          -  Triglycerides (TG) &gt; 200 to &lt;750 mg/dL&#xD;
&#xD;
          -  Able to understand and cooperate with study procedures, and have signed a written&#xD;
             informed consent prior to any study procedures.&#xD;
&#xD;
          -  Willing to maintain a stable diet and level of activity throughout the trial. Willing&#xD;
             to maintain current activity level and diet throughout the trial.&#xD;
&#xD;
          -  If, of childbearing age, must be on a medically approved form of birth control as&#xD;
             identified by the investigator in this trial&#xD;
&#xD;
          -  History (&gt; 3 months) of taking a statin medication (HMG-CoA reductase inhibitor,&#xD;
             including Lipitor, Zocor, Crestor, Pravachol, Lescol, Livalo) without problems, and&#xD;
             would be willing to withdraw from statin for the duration of the trial (4 weeks&#xD;
             without statin prior to randomization for washout period, then treatment with protocol&#xD;
             medication for 10 week duration of the trial)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals with intolerance of, or allergy to red yeast rice or omega 3 fatty acids.&#xD;
&#xD;
          -  Individuals currently taking a statin (HMG-CoA Reductase inhibitor) including Lipitor,&#xD;
             Zocor, Crestor, Pravachol, Lescol, Livalo) or other lipid metabolism altering product&#xD;
             within four (4) weeks prior to randomization who do not wish to withdraw from therapy.&#xD;
&#xD;
          -  Individual taking prescription or over the counter medications (including dietary&#xD;
             supplements) known to alter lipid metabolism within four (4) weeks of randomization.&#xD;
             Medications excluded within 4 weeks of randomization are: prescription omega-3 fatty&#xD;
             acids, statins, bile acid sequestrants, cholesterol absorption inhibitors, niacin or&#xD;
             fibrates. Dietary supplements excluded within 4 weeks prior to randomization are:&#xD;
             L-carnitine, policosanol, guggulipid, sterol/stanol products, red rice yeast&#xD;
             supplements, garlic supplements, soy isoflavone supplements, niacin or its analogues,&#xD;
             probiotics and dietary fiber supplements (including &gt;2 teaspoons Metamucil or&#xD;
             psyllium-containing supplements per day and prebiotics), or any dietary supplement or&#xD;
             vitamin complex product containing omega 3 acids or fish oil.&#xD;
&#xD;
          -  Use of systemic corticosteroids, androgens (except androgens for hypogonadism to&#xD;
             restore normal levels), phenytoin, erythromycin and other macrolides, and thyroid&#xD;
             hormones (except stable-dose thyroid replacement therapy for four (4) weeks prior to&#xD;
             enrollment).&#xD;
&#xD;
          -  Use of the anticoagulants warfarin (Coumadin) or dabigatran (Pradaxa), apixaban&#xD;
             (Eliquis) or rivaroxaban (Xarelto).&#xD;
&#xD;
          -  Pregnant or lactating women, or women of childbearing potential who are not complying&#xD;
             with an approved method of contraception. A woman is considered to be of childbearing&#xD;
             potential unless she is post-hysterectomy, one or more years postmenopausal, or one or&#xD;
             more years post-tubal ligation.&#xD;
&#xD;
          -  Individuals with a history of myopathy, defined as a creatine phosphokinase (CPK) &gt;450&#xD;
             U/L and/or unexplained muscle pain on statins.&#xD;
&#xD;
          -  Type I or type II diabetes mellitus or HbA1c ≥7.0%&#xD;
&#xD;
          -  History of significant cardiovascular or coronary heart disease (CVD or CHD) as&#xD;
             defined by having had a coronary artery bypass procedure, coronary stent or&#xD;
             angioplasty, or myocardial infarction.&#xD;
&#xD;
          -  Current or recent (within six months) history of significant gastrointestinal, renal,&#xD;
             pulmonary, hepatic or biliary disease&#xD;
&#xD;
          -  History of cancer, other than non-melanoma skin cancer and basal cell carcinoma,&#xD;
             within the previous five years.&#xD;
&#xD;
          -  Poorly controlled or uncontrolled hypertension (systolic blood pressure ≥160 mm Hg&#xD;
             and/or diastolic blood pressure ≥95 mm Hg).&#xD;
&#xD;
          -  Recent history (within past 6 months) of excessive alcohol use, defined as &gt;14 drinks&#xD;
             per week (One drink = 12 oz. beer, 4 oz. wine, 1.5 oz. hard liquor).&#xD;
&#xD;
          -  Exposure to any investigational agent within 4 weeks prior to Visit 1.&#xD;
&#xD;
          -  Has a condition the Investigator believes would interfere with the evaluation of the&#xD;
             subject, or may put the subject at undue risk during the course of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Becker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chestnut Hill Temple Cardiology</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>February 20, 2014</study_first_submitted>
  <study_first_submitted_qc>February 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2014</study_first_posted>
  <last_update_submitted>December 10, 2015</last_update_submitted>
  <last_update_submitted_qc>December 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>low density lipoprotein cholesterol</keyword>
  <keyword>triglycerides</keyword>
  <keyword>mixed hyperlipoproteinemia</keyword>
  <keyword>Dehydroascorbic Acid</keyword>
  <keyword>Eicosapentaenoic Acid</keyword>
  <keyword>Fish oil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemia, Familial Combined</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type V</mesh_term>
    <mesh_term>Lipidoses</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

